News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

This was the stock's second consecutive day of gains.

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.48% to $672.98 Friday, on what proved to be an all-around grim ...

If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price lowered by equities researchers at Bernstein Bank from $1,070.00 to $1,000.00 in a research note issued to investors on ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...